Responses
Immune cell therapies and immune cell engineering
Original research
Off-the-shelf CAR-NK cells targeting immunogenic cell death marker ERp57 execute robust antitumor activity and have a synergistic effect with ICD inducer oxaliplatin
Compose a Response to This Article
Other responses
No responses have been published for this article.
